Abstract
Antisense oligonucleotides (AONs) are one of the several types of “antisense therapeutics” designed to modulate specific gene expression at the mRNA level. Although antisense strategies also include ribozymes (RNA enzyme) and, more recently, DNAzymes (a DNA analog of a ribozyme), AONs are by far the most advanced in clinical development and will be the focus of this review.
Keywords
- Anticancer Therapeutics
- A549 Human Lung Cancer Cell
- Target mRNA Sequence
- Fluid Phase Pinocytosis
- Antisense Therapeutics
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReference
Monia, B. P., Sasmor, H., Johnston, J. F., Freier, S. M, Lesnik, E. A., Muller, M., et al. (1996) Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA 93, 15481–15484.
Mukhopadhyay, T. and Roth, J. A. (1996) Antisense regulation of oncogenes in human cancer. Crit. Rev. Oncog. 7, 151–190.
Lima, W. F., Brown-Driver, V., Fox, M., Hanecak, R., and Bruice, T. W. (1997) Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. 272, 626–638.
Milner, N., Mir, K. U., and Southern, E. M. (1997) Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol. 15, 537–541.
Agrawal, S. and Zhao, Q. (1998) Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug. Dev. 8, 135–139.
Agrawal, S., Zhang, X., Lu, Z., Zhao, H., Tamburin, J. M., Yan, J., et al. (1995) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharmacol. 50, 571–576.
Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawal, S., and Zhang, R. (1999) Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 96, 13989–13994.
Zhang, R., Lu, Z., Zhao, H., Zhang, X., Diasio, R. B., Habus, I., et al. (1995) In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50, 545–556.
Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R., and Nicklin, P. L. (1997) Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol. 54, 657–668.
Zhao, Q., Song, X., Waldschmidt, T., Fisher, E., and Krieg, A. M. (1996) Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood 88, 1788–1795.
Crooke, S. T. (1996) Progress in antisense therapeutics. Med. Res. Rev. 16, 319–344.
Yokozaki, H., Budillon, A., Tortora, G., Meissner, S., Beaucage, S. L., Miki, K., et al. (1993) An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res. 53, 868–872.
Yazaki, T., Ahmad, S., Chahlavi, A., Zylber-Katz, E., Dean, N. M., Rabkin, S. D., et al. (1996) Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50, 236–242.
Nesterova, M. and Cho-Chung, Y. S. (1995) A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat. Med. 1, 528–533.
Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549.
Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J., and Krieg, A. M. (1996) CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93, 2879–2883.
Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., and Stein, C. A. (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620–2627.
Barton, C. M. and Lemoine, N. R. (1995) Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br. J. Cancer 71, 429–437.
Wooldridge, J. E., Ballas, Z., Krieg, A. M., and Weiner, G. J. (1997) Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89, 2994–2998.
Jansen, B., Wadl, H., Inoue, S. A., Trulzsch, B., Selzer, E., Duchene, M., et al. (1995) Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism. Antisense Res. Dev. 5, 271–277.
Galbraith, W. M., Hobson, W. C., Giclas, P. C., Schechter, P. J., and Agrawal, S. (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4, 201–206.
Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M., and Hancock, J. F. (1994) Activation of Raf as a result of recruitment to the plasma membrane. Science 264, 1463–1467.
Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2, 668–675.
Stevenson, J. P., Yao, K. S., Gallagher, M., Friedland, D., Mitchell, E. P., Cassella, A., et al. (1999) Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17, 2227–2236.
Cunningham, C. C., Holmlund, J. T., Schiller, J. H., Geary, R. S., Kwoh, T. J., Dorr, A., et al. (2000) A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 6, 1626–1631.
Stevenson, J. P., Gallagher, M., et al. (1999) Phase I trial of the c-Raf-1 antisense oligonucleotide ISIS 5132 administered as a 21-day continuous infusion in combination with 5-FU and Leucovorin as a daily X 5 bolus. AACR/NCI/EORTC International conference. Washington, DC, 1999, Abstract 579.
O’Dwyer, P. J., Stevenson, J. P., Gallagher, M., Cassella, A., Vasilevskaya, I., Monia, B. P., et al. (1999) c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res. 5, 3977–3982.
Dean, N., McKay, R., Miraglia, L., Howard, R., Cooper, S., Giddings, J., et al. (1996) Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res. 56, 3499–3507.
Nemunaitis, J., Von Hoff, D. D., Holmlund, J., Dorr, A., and Eckhardt, S. G. (1998) Phase I pharmacokinetic (PK) trial of a protein kinase C-alpha antisense oligonucleotide, ISIS 3521 (CGP 64128A), administered thrice weekly. Proc. Am. Soc. Clin. Oncol., Abstract 812.
Sikic, B. I., Yuen, A. R., Advani, R., Halsey, J., Fisher, G. A., Holmlund, J., et al. (1998) Antisense oligonucleotide targeted to protein kinase C-alpha (ISIS 3521/CGP 64128A) by 21-day continuous intravenous infusion:results of the Phase I trail and activity in ovraina carcinomas (Meeting abstract). Proc. Am. Soc. Clin. Oncol., Abstract 1654.
Yuen, A., Halsey, J., Fisher, G., Advani, R., Moore, M., Saleh, M., et al. (2001) A Phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer. Am. Soc. Clin. Oncol., San Francisco, Abstract.
Slebos, R. J. and Rodenhuis, S. (1992) The ras gene family in human non-small-cell lung cancer. J. Natl. Cancer Inst. Monogr. 13, 23–29.
Dang, T., Johnson, D. H., Kelly, K., Rizvi, N., Holmlund, J., and Dorr, A. (2001) Multicenter Phase II Trial of an Antisense Inhibitor of H-ras (ISIS-2503) in Advanced Non-Small Cell Lung Cancer (NSCLC). American Society of Clinical Oncology, San Francisco, Abstract 1325.
Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., et al. (1993) bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med. 329, 690–694.
Yan, J. J., Chen, F. F., Tsai, Y. C., and Jin, Y. T. (1996) Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. Oncology 53, 6–11.
Koty, P. P., Zhang, H., and Levitt, M. L. (1999) Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23, 115–127.
Ziegler, A., Luedke, G. H., Fabbro, D., Altmann, K. H., Stahel, R. A., and Zangemeister-Wittke, U. (1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst. 89, 1027–1036.
Zangemeister-Wittke, U., Schenker, T., Luedke, G. H., and Stahel, R. A. (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. Cancer 78, 1035–1042.
Yang, D., Ling, Y., Almazan, M., Guo, R., Murray, A., Brown, B., et al. (1999) Tumor regression of human breast carcinomas by combination therapy of anti-bcl-2 antisense oligoneucleotide and chemotherapeutic drugs. Proceedings of AACR Annual Meeting, Philadelphia, PA, Abstract #4814.
Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., et al. (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4, 232–234.
Kitada, S., Takayama, S., De Riel, K., Tanaka, S., and Reed, J. C. (1994) Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev. 4, 71–79.
Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., et al. (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137–1141.
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., et al. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma [In Process Citation]. J. Clin. Oncol. 18, 1812–1823.
Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hollenstein, U., Lucas, T., et al. (1999) A Phase I–II Study with Dacarbazine and BCL-2 Antisense Oligonucleotide G3139 (GENTA) as a Chemosensitizer in Patients with Advanced Malignant Melanoma. ASCO, Atlanta, GA, Abstract #2049.
Morris, M. J., Tong, W., Osman, I., Maslak, P., Kelly, W. K., Terry, K., et al. (1999) A Phase I/IIA Dose-Escalating Trial of bcl-2 Antisense (G3139) Treatment by 14-Day Continuous Intravenous Infusion (CI) for Patients with Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies. Proc. ASCO, Atlanta, GA, Abstract #1243.
Chen, H. and Marshall, J. (2000).
Ochoa, L., Kuhn, J., Salinas, R., Hammond, L., Hao, J., Rodriguez, G., et al. (2001) G3139 downregulates the expression of BCL-2 in patients with metastatic colorectal cancer treated with irinotecan (CPT-11). AACR.
Tortora, G., Pepe, S., Bianco, C., Baldassarre, G., Budillon, A., Clair, T., et al. (1994) The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene 9, 3233–3240.
Ciardiello, F., Pepe, S., Bianco, C., Baldassarre, G., Ruggiero, A., Selvam, M. P., et al. (1993) Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int. J. Cancer 53, 438–443.
Tortora, G., Damiano, V., Bianco, C., Baldassarre, G., Bianco, A. R., Lanfrancone, L., et al. (1997) The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene 14, 923–928.
Rohlff, C. and Glazer, R. I. (1995) Regulation of multidrug resistance through the cAMP and EGF signalling pathways [published erratum appears in Cell Signal 1996 Feb;8(2):151]. Cell Signal 7, 431–443.
Miller, W. R., Watson, D. M., Jack, W., Chetty, U., and Elton, R. A. (1993) Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res. Treat. 26, 89–94.
Simpson, B., Ramage, A., Hulme, M., Burns, D., Katsaros, D., Langdon, S., et al. (1996) Cyclic adenosine 3′,5′-monophosphage-binding proteins in human ovarian cancer: correlation with clinicopathological features. Clinical Cancer Res. 2, 201–206.
Tortora, G., Yokozaki, H., Pepe, S., Clair, T., and Cho-Chung, Y. S. (1991) Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA 88, 2011–2015.
Tortora, G., Caputo, R., Damiano, V., Bianco, R., Pepe, S., Bianco, A. R., et al. (1997) Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc. Natl. Acad. Sci. USA 94, 12586–12591.
Tortora, G., Caputo, R., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., et al. (1999) Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth [In Process Citation]. Clin. Cancer Res. 5, 875–881.
Chen, H. X., Marshall, J. L., Ness, E., Martin, R. R., Dvorchik, B., Rizvi, N., et al. (2000) A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors [In Process Citation]. Clin. Cancer Res. 6, 1259–1266.
Yuen, A., Advani, R., Fisher, G., Halsey, J., Lum, B., Geary, R., et al. (2000) A Phase I/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer. American Society of Clinical Oncology, New Orleans, Abstract 1802.
Stewart, D., Donehower, R., Eisenhauer, E., Winman, N., Moore, M., Bonfils, C., et al. (2000) A Phase I and Pharmacokinetic study of MG98, a human DNA mehtyltransferase (MeTase) antisense oligonucleotide, given as a 2-hour twice weekly infusion 3 out of 4 weeks. 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, 2000, Abstract #528.
Wright, J. A., Feng, N. P., Jin Hong, N., Wang, M., Lee, Y., and Young, A. (2001) GTI-2501, an outstanding antisense antitumor agent that targets the R1 component of human ribonucleotide reductase. American Association of Cancer Research, Abstract #4560.
Gewirtz, A. M., Luger, S., Sokol, D., Gowdin, B., Studmauer, E., Reecio, A., and Ratajczak, M. Z. (1996) Oligonucleotide therapeutics for human myelogenous leukemia: Interim results. Amer. Soc. Hematol. Abstract #1069.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Chen, H.X. (2003). Clinical Development of Antisense Oligonucleotides as Anti-Cancer Therapeutics. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicine™, vol 75. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-324-0:621
Download citation
DOI: https://doi.org/10.1385/1-59259-324-0:621
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-920-9
Online ISBN: 978-1-59259-324-8
eBook Packages: Springer Protocols